1/27/2014 11:51:27 AM
Sunnyvale, California – January 27, 2014 – Sorbent Therapeutics, Inc., a biopharmaceutical
company developing therapies for cardiovascular and renal diseases, today announced that Tom
O’Neil has joined the company as Chief Financial Officer. Mr. O’Neil brings more than 15 years
of industry experience to Sorbent. In this role, he will oversee Sorbent’s financial operations,
reporting directly to Detlef Albrecht, M.D., Sorbent’s President and Chief Executive Officer.
“Tom brings significant experience in corporate finance and is a welcome addition to our
leadership team,” said Dr. Albrecht. “Tom brings key skills and expertise that are highly relevant
to Sorbent’s business today and to our future growth, including clinical-stage and commercial
financial management, private and public financing, strategic planning, and a wide range of
corporate development activities.”
“With Phase 2b clinical data for CLP-1001 in heart failure expected later this year, this is an
exciting time to join Sorbent,” said Mr. O’Neil. “I look forward to working with Detlef, the
management team and Sorbent's Board of Directors to help realize the full potential of CLP-1001
and other product candidates in Sorbent’s pipeline."
Mr. O’Neil has more than 15 years of finance and operations experience in start-ups through
large public companies. Previously, Mr. O’Neil was Vice President, Finance & Administration for
ChemGenex Pharmaceuticals, a publicly traded Australian company, prior to its acquisition by
Cephalon, Inc. (subsequently acquired by Teva Pharmaceuticals). Before ChemGenex, he was
Vice President, Finance & Administration for venture capital-backed biotechnology start-ups,
Nodality and HX Diagnostics. Prior to that, Mr. O’Neil held several finance roles at Monogram
Biosciences, Inc. (acquired by LabCorp). Mr. O’Neil’s experience includes the oversight and
management of equity and debt financings, initial public offerings, merger and acquisitions,
collaborations, and investor relations. He has an M.B.A. from the University of California, Los
Angeles, Anderson Graduate School of Management, and a B.A. from Pomona College.
Sorbent Therapeutics is a private biopharmaceutical company developing therapies for patients
requiring targeted cation and fluid removal from the body. The company is focused on the
development of non-absorbed polymeric drugs to satisfy unmet clinical needs in large
cardiovascular and renal markets such as heart failure, end-stage renal disease, chronic kidney
disease and hypertension. Sorbent is headquartered in Sunnyvale, California. For more
information, visit www.sorbent.com.
Detlef F. Albrecht, M.D.
President and CEO
BCC Partners, LLC
Karen L. Bergman or Michelle Corral
650.575.1509 or 415.794.8662
Help employers find you! Check out all the jobs and post your resume.
comments powered by